IT 603
Alternative Names: IT-603Latest Information Update: 28 Sep 2020
Price :
$50 *
At a glance
- Originator ImmuneTarget
- Class Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Graft-versus-host disease; Transplant rejection
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Graft-versus-host-disease in USA
- 28 Sep 2020 No recent reports of development identified for preclinical development in Transplant-rejection(Prevention) in USA
- 10 Aug 2016 IT 603 is available for licensing as of 10 Aug 2016. http://www.immunetarget.com/